ReviewMolecular medicine (Cambridge, Mass.)2026
Monogenic forms of inflammatory bowel disease: Genetic mechanisms, models, and clinical implications.
Review in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From signals to systems: the epigenetic-microbiome-mitochondrial axis in IBD pathogenesis.Gut microbes · 2026Review
- Clinical Phenotypes and Genetic Findings in Very-Early-Onset Inflammatory Bowel Disease: A Vietnamese Pediatric Cohort Study.Children (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory bowel disease (IBD) is a chronic disease that lead to impaired quality of life, affecting individuals across diverse age groups and ethnic backgrounds. Despites extensive research, the etiology and the underlying mechanisms of IBD remain unclear. However, genetic, epigenetic, immune, and environmental factors are recognized as critical contributors to the onset, progression, and persistence of the disease. MAIN BODY: Over the last decades, genome-wide association studies (GWAS) and high-throughput sequencing have identified numerous common risk loci and rare pathogenic variants associated with IBD, while emerging multi-omics approaches are expected to refine how these genetic factors affect specific cell types and pathways involved in IBD pathogenesis. In-depth studies using distinct in vitro and in vivo models have further elucidated the impact of these variants on intestinal inflammation, enhancing our understanding of the genetic basis of certain forms of IBD. Although, the interaction of these variants with environmental triggers is yet to be investigated. These models have also opened new avenues for the development of diagnostic and therapeutic strategies.
conclusionThis review focuses on the genetic bases of IBD, with a particular emphasis on its monogenic forms, and highlights the role of in vitro and in vivo models in unraveling IBD pathogenesis and advancing treatment modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.